DelveInsight reports that over five key companies are actively engaged in developing more than five CAR T-Cell Therapy treatments for Multiple Myeloma.
CAR T-Cell Therapy for Multiple Myeloma Overview:
Multiple Myeloma, also known as Kahler’s disease, is a blood cancer that affects plasma cells, a type of white blood cell responsible for producing antibodies. In people with multiple myeloma, these plasma cells produce excessive immunoglobulins, causing damage to various organs.
This rare condition is classified into two main types based on its effects on the body: indolent myeloma, which progresses slowly without forming bone tumors and involves a slight increase in monoclonal (M) plasma cells and protein, and solitary plasmacytoma, which usually leads to tumor formation in bone.
Although multiple myeloma is not curable, treatments can help slow its progression. One promising method is CAR T-cell therapy, an innovative approach that uses genetically modified T cells to create chimeric antigen receptors (CARs). These receptors allow T cells to identify and destroy cancer cells. CAR T-cell therapies for multiple myeloma target B-cell maturation antigen (BCMA), a protein present on myeloma cells but not on healthy cells, providing a more targeted and effective treatment option.
Request for a detailed insights report on CAR T-Cell Therapy for Multiple Myeloma pipeline insights
“CAR T-Cell Therapy for Multiple Myeloma Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the CAR T-Cell Therapy for Multiple Myeloma Therapeutics Market.
Key Takeaways from the CAR T-Cell Therapy for Multiple Myeloma Pipeline Report
-
DelveInsight’s CAR T-Cell Therapy for Multiple Myeloma pipeline report highlights a dynamic landscape with more than five active companies developing over five therapies for this treatment area. Leading firms such as Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation, and others are exploring new drug candidates to advance multiple myeloma treatment options.
-
Promising pipeline therapies in various development stages include PHE 885, JNJ-68284528, and others. On March 11, 2025, Bristol Myers Squibb announced its acquisition of 2seventy bio, a company focused on cancer cell therapies, for about $286 million, aiming to strengthen its CAR T-cell therapy portfolio, especially regarding its existing treatment, Abecma.
-
Arcellx reported encouraging clinical trial results for its CAR-T therapy, anito-cel, with a 97% response rate and 62% of patients achieving complete responses, positioning anito-cel as a strong competitor to therapies like Carvykti. A three-year study showed that Carvykti lowered the risk of death by 45% in multiple myeloma patients, highlighting its significant survival benefit.
-
Approved by the FDA in February 2022, Carvykti is indicated for adults with relapsed or refractory multiple myeloma after four or more prior therapies. Clinical trials demonstrated an overall response rate (ORR) of 97.9% and a median duration of response lasting 21.8 months.
CAR T-Cell Therapy for Multiple Myeloma Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the CAR T-Cell Therapy for Multiple Myeloma Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CAR T-Cell Therapy for Multiple Myeloma treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the CAR T-Cell Therapy for Multiple Myeloma market.
Download our free sample page report on CAR T-Cell Therapy for Multiple Myeloma pipeline insights
CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs
-
PHE 885: Novartis Pharmaceuticals
-
JNJ-68284528: Janssen Biotech
CAR T-Cell Therapy for Multiple Myeloma Companies
Around five or more leading companies are actively working on developing CAR T-Cell therapies for Multiple Myeloma. Among these, Novartis Pharmaceuticals and others have drug candidates in various stages of development, ranging from early Phase I trials to more advanced phases.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
CAR T-Cell Therapy for Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
CAR T-Cell Therapy for Multiple Myeloma Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging CAR T-Cell Therapy for Multiple Myeloma Therapies and Key Companies: CAR T-Cell Therapy for Multiple Myeloma Clinical Trials and advancements
CAR T-Cell Therapy for Multiple Myeloma Pipeline Therapeutic Assessment
• CAR T-Cell Therapy for Multiple Myeloma Assessment by Product Type
• CAR T-Cell Therapy for Multiple Myeloma By Stage
• CAR T-Cell Therapy for Multiple Myeloma Assessment by Route of Administration
• CAR T-Cell Therapy for Multiple Myeloma Assessment by Molecule Type
Download CAR T-Cell Therapy for Multiple Myeloma Sample report to know in detail about the CAR T-Cell Therapy for Multiple Myeloma treatment market @ CAR T-Cell Therapy for Multiple Myeloma Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. CAR T-Cell Therapy for Multiple Myeloma Current Treatment Patterns
4. CAR T-Cell Therapy for Multiple Myeloma – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. CAR T-Cell Therapy for Multiple Myeloma Late-Stage Products (Phase-III)
7. CAR T-Cell Therapy for Multiple Myeloma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. CAR T-Cell Therapy for Multiple Myeloma Discontinued Products
13. CAR T-Cell Therapy for Multiple Myeloma Product Profiles
14. CAR T-Cell Therapy for Multiple Myeloma Key Companies
15. CAR T-Cell Therapy for Multiple Myeloma Key Products
16. Dormant and Discontinued Products
17. CAR T-Cell Therapy for Multiple Myeloma Unmet Needs
18. CAR T-Cell Therapy for Multiple Myeloma Future Perspectives
19. CAR T-Cell Therapy for Multiple Myeloma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the CAR T-Cell Therapy for Multiple Myeloma Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/